Tue, January 21, 2025
Mon, January 20, 2025
[ Mon, Jan 20th ] - WOFL
10 new museums opening in 2025
Sun, January 19, 2025
Sat, January 18, 2025
[ Sat, Jan 18th ] - MSN
Best Minecraft Tech Mods
Fri, January 17, 2025
Thu, January 16, 2025
Wed, January 15, 2025
Tue, January 14, 2025
Mon, January 13, 2025
[ Mon, Jan 13th ] - NASA
Earth Science at Work
Sun, January 12, 2025
Sat, January 11, 2025

AbbVie and Simcere Zaiming link to develop trispecific antibody


//science-technology.news-articles.net/content/2 .. aiming-link-to-develop-trispecific-antibody.html
Published in Science and Technology on Wednesday, January 15th 2025 at 17:22 GMT by MSN   Print publication without navigation

  • The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory MM.

AbbVie, a leading biopharmaceutical company, has entered into a collaboration with Simcere Zaiming, a Chinese biotech firm, to develop a trispecific antibody aimed at treating cancer. This partnership leverages Simcere Zaiming's expertise in trispecific T cell-engaging antibodies, which are designed to simultaneously target three different antigens, potentially enhancing the effectiveness of cancer immunotherapy. The agreement includes AbbVie making an upfront payment to Simcere Zaiming, with further milestone payments and royalties on future sales if the product successfully reaches the market. This collaboration not only signifies AbbVie's commitment to expanding its oncology portfolio but also highlights the growing trend of international partnerships in the biotech industry to accelerate drug development.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/abbvie-and-simcere-zaiming-link-to-develop-trispecific-antibody/ar-AA1xgBc4 ]

Publication Contributing Sources